FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136970655> ?p ?o ?g. }

• W2136970655 abstract "Adding antiangiogenic therapy to standard chemotherapy has improved response rates and progression-free survival in metastatic breast cancer (BC) patients. This phase II study evaluated cardiac safety of bevacizumab with/without trastuzumab with two docetaxel-based regimens in early BC.127 women with non-metastatic node-positive or high-risk node-negative BC were enrolled. Women with human epidermal growth factor receptor 2 (HER2)-negative BC (n = 93) received docetaxel/doxorubicin/cyclophosphamide (TAC) + bevacizumab, while women with HER2-positive disease (n = 34) received docetaxel/carboplatin/trastuzumab (TCH) + bevacizumab, every 3 weeks for six cycles. Maintenance therapy with bevacizumab alone or bevacizumab plus trastuzumab, respectively, was given every 3 weeks for 52 weeks. The primary objective was to evaluate cardiac safety, as measured by the incidence of ≥ grade 3 clinical congestive heart failure (CHF); the secondary objective was assessment of safety and toxicity.At least one cardiac adverse event (AE; CHF, cardiomyopathy, or left ventricular dysfunction) was reported in 26.1% of TAC (n = 92) and 17.6% of TCH subjects (n = 34); there were no cardiac deaths. ≥ Grade 3 clinical CHF was observed in 4.3% in the TAC plus bevacizumab stratum and 0% in the TCH plus bevacizumab stratum. A ≥ grade 3 treatment-emergent AE (any kind) related to study treatment was observed in 59.8% in the TAC with bevacizumab and 52.9% in the TCH plus bevacizumab stratum.Adding bevacizumab to a docetaxel-based regimen with trastuzumab did not appear to increase cardiotoxicity.ClinicalTrials.gov Identifier: NCT00446030, registered March 8, 2007." @default.
• W2136970655 created "2016-06-24" @default.
• W2136970655 creator A5015491002 @default.
• W2136970655 creator A5016295064 @default.
• W2136970655 creator A5047821786 @default.
• W2136970655 creator A5060675145 @default.
• W2136970655 creator A5066452345 @default.
• W2136970655 creator A5068059897 @default.
• W2136970655 creator A5068891265 @default.
• W2136970655 creator A5074044801 @default.
• W2136970655 creator A5089040548 @default.
• W2136970655 date "2014-05-12" @default.
• W2136970655 modified "2023-09-27" @default.
• W2136970655 title "Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer" @default.
• W2136970655 cites W1968449590 @default.
• W2136970655 cites W2026989222 @default.
• W2136970655 cites W2032037224 @default.
• W2136970655 cites W2098775844 @default.
• W2136970655 cites W2101760255 @default.
• W2136970655 cites W2108182027 @default.
• W2136970655 cites W2120639027 @default.
• W2136970655 cites W2126275851 @default.
• W2136970655 cites W2135800076 @default.
• W2136970655 cites W2138440511 @default.
• W2136970655 cites W2139927762 @default.
• W2136970655 cites W2146384083 @default.
• W2136970655 cites W2152142449 @default.
• W2136970655 cites W2153982924 @default.
• W2136970655 cites W2160082612 @default.
• W2136970655 cites W2168236082 @default.
• W2136970655 cites W2169961966 @default.
• W2136970655 doi "https://doi.org/10.1186/2193-1801-3-244" @default.
• W2136970655 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4031367" @default.
• W2136970655 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24860718" @default.
• W2136970655 hasPublicationYear "2014" @default.
• W2136970655 type Work @default.
• W2136970655 sameAs 2136970655 @default.
• W2136970655 citedByCount "6" @default.
• W2136970655 countsByYear W21369706552015 @default.
• W2136970655 countsByYear W21369706552016 @default.
• W2136970655 countsByYear W21369706552017 @default.
• W2136970655 countsByYear W21369706552019 @default.
• W2136970655 countsByYear W21369706552020 @default.
• W2136970655 countsByYear W21369706552023 @default.
• W2136970655 crossrefType "journal-article" @default.
• W2136970655 hasAuthorship W2136970655A5015491002 @default.
• W2136970655 hasAuthorship W2136970655A5016295064 @default.
• W2136970655 hasAuthorship W2136970655A5047821786 @default.
• W2136970655 hasAuthorship W2136970655A5060675145 @default.
• W2136970655 hasAuthorship W2136970655A5066452345 @default.
• W2136970655 hasAuthorship W2136970655A5068059897 @default.
• W2136970655 hasAuthorship W2136970655A5068891265 @default.
• W2136970655 hasAuthorship W2136970655A5074044801 @default.
• W2136970655 hasAuthorship W2136970655A5089040548 @default.
• W2136970655 hasBestOaLocation W21369706551 @default.
• W2136970655 hasConcept C121608353 @default.
• W2136970655 hasConcept C126322002 @default.
• W2136970655 hasConcept C143998085 @default.
• W2136970655 hasConcept C2776694085 @default.
• W2136970655 hasConcept C2777802072 @default.
• W2136970655 hasConcept C2778233292 @default.
• W2136970655 hasConcept C2778239845 @default.
• W2136970655 hasConcept C2779786085 @default.
• W2136970655 hasConcept C2781190966 @default.
• W2136970655 hasConcept C2781413609 @default.
• W2136970655 hasConcept C2781451048 @default.
• W2136970655 hasConcept C530470458 @default.
• W2136970655 hasConcept C71924100 @default.
• W2136970655 hasConceptScore W2136970655C121608353 @default.
• W2136970655 hasConceptScore W2136970655C126322002 @default.
• W2136970655 hasConceptScore W2136970655C143998085 @default.
• W2136970655 hasConceptScore W2136970655C2776694085 @default.
• W2136970655 hasConceptScore W2136970655C2777802072 @default.
• W2136970655 hasConceptScore W2136970655C2778233292 @default.
• W2136970655 hasConceptScore W2136970655C2778239845 @default.
• W2136970655 hasConceptScore W2136970655C2779786085 @default.
• W2136970655 hasConceptScore W2136970655C2781190966 @default.
• W2136970655 hasConceptScore W2136970655C2781413609 @default.
• W2136970655 hasConceptScore W2136970655C2781451048 @default.
• W2136970655 hasConceptScore W2136970655C530470458 @default.
• W2136970655 hasConceptScore W2136970655C71924100 @default.
• W2136970655 hasIssue "1" @default.
• W2136970655 hasLocation W21369706551 @default.
• W2136970655 hasLocation W21369706552 @default.
• W2136970655 hasLocation W21369706553 @default.
• W2136970655 hasLocation W21369706554 @default.
• W2136970655 hasLocation W21369706555 @default.
• W2136970655 hasOpenAccess W2136970655 @default.
• W2136970655 hasPrimaryLocation W21369706551 @default.
• W2136970655 hasRelatedWork W2004818507 @default.
• W2136970655 hasRelatedWork W2011967246 @default.
• W2136970655 hasRelatedWork W2052405826 @default.
• W2136970655 hasRelatedWork W2075810095 @default.
• W2136970655 hasRelatedWork W3200352014 @default.
• W2136970655 hasRelatedWork W4232759728 @default.
• W2136970655 hasRelatedWork W4232824905 @default.
• W2136970655 hasRelatedWork W4233675113 @default.
• W2136970655 hasRelatedWork W4255825072 @default.
• W2136970655 hasRelatedWork W4298186602 @default.
• W2136970655 hasVolume "3" @default.

• next